Abnormally active CXCL13/CXCR5 signaling enhances cancer cell growth through complex and different mechanisms in breast cancer [39,40], intestinal cancer [32,41], lung cancer [42], prostate cancer [43,44,45], oral squamous cell carcinoma [46,47], renal cell carcinoma [48], neuroblastoma [49,50], and lymphoma [51,52]. This evidence concerns the gene CXCR5 and cancer.